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Chapter 1: Summary  
 
Background: Differentiation between surgical bleeding and coagulopathy is critical 
as re-exploration is associated with increases in mortality and morbidity. Adequate 
reversal of heparin with protamine at the end of cardiopulmonary bypass (CPB) is 
critical to prevent postoperative bleeding. Meticulous dosing of protamine is required 
as excessive dosages has deleterious side effects on clotting. Traditional methods 
make use of an activated clotting time (ACT) for evaluation of adequate heparin 
reversal. However, recent use of other point of care (POC) tests, the 
thromboelastogram (TEG®) has started challenging the utility and exclusive use of 
ACT to evaluate effective reversal. Differences between thromboelastographic R-
kaolin and R-heparinase times is an indicator of residual heparin. However, the exact 
relationship between these parameters and the exact amount of residual heparin is 
unknown. The rationale for this study was to accurately determine the relationship 
between the magnitude of the R-kaolin and R-heparinase time difference and blood 
heparin concentrations. 
Aims: This study was performed to define the in-vitro relationship between the 
difference between the thromboelastographic R-kaolin and R-heparinase time 
difference (TEG® Delta-kh R-time) and plasma heparin concentrations. The primary 
outcome was to determined the relationship between the TEG® Delta-kh R-time 
difference and heparin concentrations. The secondary outcome was to determine the 
concentration of heparin at or below which R-kaolin times become measureable. 
Methods:  
This was a single centre, prospective, randomized laboratory study. Following 
institutional ethics approval and informed consent, sixty-two samples were taken 
during CPB from 20 patients meeting inclusion criteria. Samples were randomized to 
one of three groups which would dictate the protamine dose. The three groups were 
based on a protamine to heparin ratio (expressed as milligram protamine per milligram 
heparin administered to the patient) approximating 0.25, 0.5, and 0.75 mg/mg 
respectively. Each sample of blood was then administered a dose of protamine. The 
TEG® analysis entailed measuring the R-kaolin and R-heparinase time and noting the 
difference.  Thereafter, each blood sample was sent for heparin concentration 
determination using an anti-Xa activity assay. 
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Results: 
No relationship between the measurable R-kaolin time and heparin concentration 
could be demonstrated (p=0.80), as well as no relationship between measurable 
TEG® Delta-kh R- time difference and heparin activity (p=0.42). However, we did 
identify a high probability to be able to predict a measurable R-kaolin time (negative 
predictive value 90%, 95% CI 74% to 98%) when heparin concentration is less than 
1.24IU/ml. 
Conclusions:  
We were unable to predict heparin concentration using TEG® in this study.  It is likely 
that this was related to methodological problems. The protamine dose was a complex 
calculation and there is uncertainty with regard to the actual amounts used. There 
were also multiple laboratory technicians, with a possible loss of standardization. 
 
However, R-kaolin time will likely be measurable at heparin concentrations below 1.24 
IU/ml, and not measurable above that value. This observation is immensely valuable 
for clinicians and researchers. Future studies should take this into account and attempt 
to determine the relationship between TEG® Delta-kh R- time differences and heparin 
activity only when heparin concentration are less than 1.24IU/ml.  
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Opsomming 
 
Agtergrond 
Onderskeiding tussen chirurgiese bloeding en koagulopatie is krities belangrik, want 
hereksplorasie is geassosieer met ‘n toename in mortaliteit en morbiditeit. Die 
voldoende omkeuring van heparien met protamien aan die einde van 
Kardiolpulmonêre omleiding (KPO) is krities om postoperatiewe bloeding te voorkom. 
Noukeurige dosering van Protamien word benodig aangesien oormatige dosering 
nadelige newe-effekte op stolling. Geaktiveerde Sollingstyd (ACT) word gebruik om 
voldoende omkeuring van Heparien te evalueer. Onlangse gebruik van Point-of-Care 
toets, Tromboelastogram (TEG®), het egter die eksklusiewe gebruik van ACT uit te 
daag. ‘n Verskil tussen Tromboelastografiek R-kaolin en R-heparienase tyd is 
aanduidend van oorblywende heparien. Die presiese verhouding tussen hierdie twee 
parameters is nie bekend nie.  Die rasionaal was om akkuraat die verhouding tussen 
die hoeveelheid van die verskil tussen die R-kaolin en R-heparienase tyd en bloed 
Heparien konsentrasies te bepaal.  
 
Doel:  
Hierdie studie was uitgevoer om die in-vitro verhouding te definieer tussen die verskil 
van Tromboelastografiek R-kaolin en R-heparienase tyd (TEG® Delta-kh R-tyd) en 
plasma heparien konsentrasies. Die primêre uitkoms was vasgestel as die verhouding 
tussen die TEG® Delta-kh R-tydsverskil en heparienaktiwiteits-konsentrasies. Die 
sekondere uitkoms was om die heparien konsentrasies te bepaal waaronder die R-
kaolin tyd meetbaar raak. 
 
Metodiek: 
Hierdie was ‘n enkel sentrum, prospektiewe gerandomiseerde laboratorium studie. Na 
institusionele etiese goedkeuring en ingeligte toestemming, is 62 monsters geneem 
tydends KPO van 20 pasiente wat die insluitings kriteria vervul het. Die monsters was 
gerandomiseer tot een van drie groepe wat die Protamien titreringsdosering sal 
dikteer.  
Die drie groepe was gebaseer op ‘n Protamien tot Heparien verhouding (uitgedruk as 
milligram protamien per milligram heparien toegedien aan die pasient) wat 0.25, 0.5, 
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en 0.75mg/mg onderskeidelik benader. ‘n Dosis Protamien was toegedien tot elke 
monster. Die TEG® analise het behels om die R-koalin en R-heparienase tyd te meet 
en die verskil daarvan aan te dui. Daarna is elke bloed monster gestuur vir die bepaling 
van die Heparien konsentrasie met die gebruik van ‘n anti-Xa aktiwiteitstoets. 
 
Resultate: 
Geen verwantskap tussen die R-kaolin tyd en Heparien konsentrasie kon getoon word 
nie. (P=0.80). Daar was ook geen verwantskap getoon tussen meetbare TEG® Delta-
kh R- tyd en Heparien aktiwiteit nie. (P=0.42). Ons het wel ‘n hoë waarskynlikheid 
geidentifiseer om die meetbare R-kaolin tyd (negatiewe voospellings waarde 90%, 
95% CI 74% tot 98%) te voorspel wanneer Heparien konsentrasie minder is as 
1.24IU/ml. 
 
Gevolgtrekking: 
Ons was nie in staat om Heparien konsentrasie te voorspel, in die studie, met die 
gebruik van TEG® nie. Dit is moontlik dat dit toegeskryf kan word aan metodieke 
tekortkominge. Die Protamien titreringsdosering was ‘n kompleks berekening en daar 
is onsekerheid oor die werklike hoeveelhede wat gebruik was. Daar was ook 
veelvuldige laboratorium tegnikuste, ten spyte van opleiding, het ‘n moontlike verlies 
van standaardisering plaasgevind. R-kaolin tyd sal egter waarskynlik meetbaar wees 
by ‘n Heparien konsentrasie onder 1.24IU/ml en nie meetbaar by konsentrasies onder 
daardie waarde nie. Die observasie is van waarde vir klinikuste en navorsers. 
Toekomstige studies moet dit in oorweging bring en probeer om die verwantskap 
tussen TEG® Delta-kh R- tydsverskil en Heparien aktiwiteit te bepaal. 
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Chapter 2: Ethics Sumission 
 
Protocol 
 
Summary  
References have been omitted from the summary. 
Title: The ability of the thromboelastogram (TEG® R-time difference between kaolin 
and heparinase) as a point of care test to predict residual heparin activity after in 
vitro protamine titration. 
Introduction, research question, hypothesis, aims and objectives: 
The anticoagulant, heparin, is used to prevent fatal clotting while the patient is on the 
heart-lung machine during cardiac surgery. The heparin is neutralised using 
protamine, a hazardous drug. Inadequate dosages of protamine will leave the patient 
anticoagulated and can lead to excessive bleeding, while excessive dosages directly 
cause a coagulopathy. The test used to identify “adequate” reversal of heparin with 
protamine, activated clotting time (ACT), is a surprisingly inaccurate marker for 
heparin reversal. Regardless of this, clinical practice still largely makes use of this 
point-of-care (POC) test.  
 
An alternative method POC test to determine if residual heparin is present and more 
protamine is needed is to use thromboelastography (TEG®). In particular, the 
difference in reaction time (R-time) between simultaneously performed ordinary TEG® 
and TEG® with heparinase (“heparinase TEG®”) has been confirmed recently as 
being a sensitive test of residual heparin. However, the exact relationship between 
these parameters has never been determined.  
 
If this study was performed after protamine has been administered to the patient (the 
logical time), the results will likely be closely grouped and not provide sufficient scatter 
to determine the relationship between the two parameters. We therefore aim to 
perform the study using blood obtained from patients while on the heart- lung machine 
to which we will add a range of protamine dosages. These blood samples will have 
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both TEG® and heparin concentrations, the latter being the gold standard, 
determined. 
 
The aim is to determine the exact relationship between the R time difference and 
heparin activity-concentration. 
 
Null Hypothesis: The difference between the R-times of kaolin and heparinase 
TEG®, is not able to predict residual heparin activity after in vitro protamine titration. 
Alternatively, R-time difference is able to predict heparin activity.  
 
A concise summary of the methodology: 
If approval is granted and eligble patients grant consent, we wish to take a sample 
containing 10 millilitres (ml) of blood (this may be repeated two times: i.e. 3 samples 
of 10 ml of blood per patient) from patients who are heparinised on cardiopulmonary 
bypass (CPB). Protamine at effective doses of 0.25, 0.5 and 0.75 mg per 100 IU (1 
mg) of heparin administered to the patient will be added to this blood sample. This 
sample will then be analysed by performing simultaneous kaolin and heparinase 
TEG®. We have clinical and research experience with TEG®. Similar quality control 
measures will be used as in previously published studies.  
 
Samples to which protamine has been added will also be taken immediately to the 
coagulation laboratory, where they will be centrifuged and stored at -80 degrees 
Celsius. Heparin is stable at this temperature. Heparin levels will be measured in the 
coagulation laboratory of Tygerberg hospital using a modified anti-Xa chromogenic 
assay, the current gold standard method of heparin level determination. 
 
The target population:  
We will aim to enrol patients undergoing cardiac surgery using cardiopulmonary 
bypass at Tygerberg Hospital. Exclusion criteria will include all patients with prior 
known coagulation abnormalities except those having received unfractionated heparin 
and/or low dose aspirin preoperatively.  
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Anticipated benefits of the study: 
This is novel research and no data on this relationship is currently available. The 
motive to undertake this research is to have a better understanding of the relationship 
of the kaolin-heparinase TEG® R- time difference and residual heparin 
concentrations. This will help us understand if this test is of use in identifing small 
residual amounts of heparin.  This would be of use to prevent bleeding at the end of 
cardiopulmonary bypass.  
 
The ethical considerations and risks for the patient: 
1. There are no risks for the patient. The main risk would be of us performing the 
study incorrectly and/or making incorrect conclusions from the study. 
2. The volume of blood removed from the patient is relatively small, the 30 ml (3 x 1o 
ml samples of blood), representing less than approximately 0,45% of the blood 
volume on cardiopulmonary bypass of a typical 70 kg patient. This should not affect 
transfusion requirements or anaemia postoperatively. 
3. Even if small errors are made in the dose of protamine, this will not matter; it is not 
the dose of either protamine or heparin that matters but the relationship between 
the R time differences and the residual heparin concentrations that we wish to 
determine. Thus scatter of the data will be of value to determine the relationship. 
4. Blood from patients on bypass will be used to perform this study: this ensures that 
any factors present during cardiopulmonary bypass that will affect the coagulation 
will be reflected by the TEG®. This study represents reality as closely as possible 
without changing practice. The heparin concentrations are also clinically relevant. 
This study could be performed by heparinising blood drawn form volunteers, then 
performing all the manipulations described above. However, whether this can be 
done in the requisite time (4 minutes) is not clear. The potential effects due to 
release of tissue factor VII and venous stasis during venepuncture is also 
eliminated with the study design chosen. The challenge of attempting to achieve 
typical heparinisation of blood is also eliminated when using this study design. 
5. We have experience in this field having published before. 
6. We have experienced technologists who perform TEG® to a high standard in a 
dedicated laboratory on a calibrated, well-maintained machine.  
7. Our laboratory has previous experience in measuring heparin concentrations. 
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Subject population: Patients undergoing cardiac surgery at Tygerberg Hospital who 
will be heparinised while on cardiopulmonary bypass. Adults > 18 years. 20 patients 
(3 samples per patient) will be required. Therefore, a total of 60 samples will be taken 
(20 patients x 3 samples per patient). 
Anticipated risks: Normal practice for patients undergoing cardiac surgery will be 
followed; this ensures representative samples will be collected. This study places no 
demands on the attending anaesthesiologist or changes in practice at all.  
Anticipated benefits: The aim of this study is to equip doctors to more easily have a 
better endpoint of heparin reversal, which would imply better patient care with less risk 
involved for subsequent patients. 
Final Ethical Considerations: There are no risks for the patient. Informed consent 
will be obtained. Patient autonomy will be respected. The study will take place in vitro 
and no new interventions are to be undertaken, and it will not influence the patient’s 
management in any way. This research study will be submitted for approval by the 
Health Research Ethics Committee (HREC). 
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Diagram of protocol: 
 
 
Sample 10 ml of blood from patient on CPB (3 samples/patient) 
 
 
Add protamine titrations to sample, use sample for 
 
 
     TEG®                 Heparin activity in blood 
(Kaolin and heparinase)                 (Anti-Xa assay in lab) 
 
 
                                    Discern relationship between parameters 
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Literature review 
 
Introduction  
Postoperative bleeding is one of the main complications after surgery involving 
cardiopulmonary bypass (CPB); indeed this complication occurs in approximately 20% 
of patients.(1) Differentiation between surgical bleeding and coagulopathy is critical. 
Re-exploration for post-operative bleeding is associated with an increase in mortality 
and morbidity.(2) A surgical cause is found in 50% of patients; therefore many re-
explorations can be avoided if a coagulopathy can be better identified and treated. 
These risks are further aggravated by the hazards, exorbitant cost and consequent 
intense scrutiny of the related transfusions that accompany postoperative bleeding. 
 
It is therefore critical to monitor coagulation during and after surgery involving CPB. 
Laboratory tests are of little value during and after CPB, this being largely due to their 
delay in results. Their role in the pre-operative setting is still useful with the activated 
partial thromboplastin time (aPTT) being sensitive to low concentration levels of 
heparin. Various point of care (POC) tests such as activated clotting time (ACT), 
thromboelastogram (TEG®) and rotational thromboelastometry (ROTEM®) are 
available for this purpose. POC tests are defined as diagnostic tests at or near the 
bedside with the ability to produce rapid results.(3) This may provide guidance for the 
attending anaesthesiologist to correctly diagnose the cause of bleeding.(4) 
Coagulation monitoring with thromboelastography has been shown to decrease 
transfusion therapy and hence an improvement in outcome and diminished costs 
overall.(5, 6) Indeed, compared to TEG®/ROTEM® guided therapy, empiric therapy 
with blood and blood products are of questionable efficacy and may be hazardous to 
the patient.(7) 
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o Residual heparin and inadequate protamine neutralisation 
o Heparin rebound phenomenon (reappearance of hypo-coaguability after 
adequate neutralisation of heparin with protamine) 
o Excess protamine (exhibits anti-platelet anticoagulant effects) 
o Hypothermia 
o Haemodilution 
o Dilution of clotting factors 
o Activation of the fibrinolytic system 
o Consumption or depletion of coagulation factors 
o Decreased or dysfunctional platelets 
o Surgical bleeding (50-70%).(1) 
Table 1. Aetiologies for coagulopathy after CPB.(6) 
 
 
o   Baseline activated clotting time test (ACT) from an arterial sample 
o   Unfractionated heparin (200 -300 IU/kg) via central venous catheter 
o   Repeat ACT after 3 minutes. Aim: 3–4 times of baseline ACT (480 seconds) 
o   Initiate CPB 
o Unfractionated heparin (5000 IU) in CPB prime solution 
o   Monitor ACT every 30 minutes during CPB 
o   Maintain ACT 400–480 seconds during hypothermia (32- 34°C) while on 
CPB 
o   Neutralise heparin with protamine after separation from CPB 
o Dose ratio 1-1,5mg protamine per 100 IU of heparin 
o   Repeat ACT after 3–5 minutes  
o Aim: return of ACT to within 10% of baseline 
Table 2: Standard anticoagulation management in our institution, TBH.  
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Apart from other causes of coagulopathy (Table 1), it is of particular importance to 
monitor adequate heparinisation and conversely, heparin neutralisation with 
protamine. Individual responses to a dose of heparin vary. Individuals may exhibit 
heparin resistance and require a higher dose due to acquired or inherited antithrombin 
III deficiency or increased protein binding of heparin.(8) At the end of surgery, it is 
critical to ensure that no residual heparin remains, potentially exposing the patient to 
the risk of developing a coagulopathy. This needs to be done in a timely manner and 
hence POC tests are ideal. It is however, of paramount importance to choose the 
correct POC test in order to ensure accuracy and meticulous protamine dosing. The 
following readily available POC tests, ACT, thromboelastogram (TEG®) and rotational 
thromboelastometry (ROTEM®) will now be discussed. 
 
Activated Clotting Time (ACT) 
Dr Paul G. Hattersley, an American pathologist, developed and subsequently 
validated the ACT test in 1966 as a test for diagnosis and management of patients 
with inherited coagulation disorders. Less than a decade later this whole blood 
coagulation assay had become a routine point of care test in surgery involving 
cardiopulmonary bypass.  
 
The ACT test has been accepted as a rational and predictable measurement of the 
intrinsic coagulation process reflecting initial fibrin formation.  The physical principle 
for this test is simple. Blood (2 ml) is placed into a glass tube containing a magnetic 
rod as well as an activator, the most common activators being kaolin or celite. The test 
tube is placed into a holder that simultaneously rotates and warms the test tube to 
37,8 degrees Celsius. Resistance to movement of the steel rod in a magnetic field 
indicates clotting and is recorded by the timer. The normal ACT value ranges from 
100-140 seconds and increases linearly with an increase in heparin concentration. 
Bull et al. set target values of 480 seconds as adequate heparin anticoagulation during 
CPB.(9, 10) This relationship is however distorted during hypothermia and 
haemodilution, thromboctyopaenia, impaired platelet function, different activators, or 
the use of aprotinin.(5, 11)  All the aforementioned factors are unfortunately common 
during CPB; they independently affect ACT test results as follows:  
o Hypothermia and haemodilution prolong ACT.(12)(17) 
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o Celite as an activator results in significantly longer ACT values than when kaolin 
is used. 
o Aprotinin produces a dose-related prolongation of celite ACT, independent of 
heparin concentrations, this may lead to the sub-therapeutic heparin 
dosing.(13). Aprotinin has been withdrawn from the international market due to 
its association with increased risk of death compared to tranexamic acid or 
aminocaproic acid.(14) 
 
Numerous iterations of the ACT device is available. Not all commercial ACT devices 
can be used interchangeably as different characteristics may exist. It is crucial to 
establish the instrument specific references values in a particular institution. For 
example, the Hemochron® system using a kaolin-based activator is a simple, widely 
used device for heparin management during and after CPB.(15) The MAX-ACT® is 
used in our institution, and may be used in conjunction with the Hemochron® 
instrument to improve accuracy according to the manufacturers. The Hepcon®  device 
is a whole blood haemostatic system providing both ACT and accurate whole blood 
heparin concentration levels using automated protamine titration.(16) 
 
ACT is relatively unreliable during the anticoagulated state, the very state we wish to 
monitor. Clinicians need to be aware of this and be cautious when making decisions 
regarding heparin neutralisation and protamine dosing based on ACT. In this respect, 
the return of the ACT to baseline is also not an absolute validation of complete heparin 
reversal as it appears that ACT is less sensitive to residual heparin than that of 
activated partial thromboplastin time (aPTT), TEG® or whole blood heparin assay.(5) 
 
 
 
Dalbert et al. compared the Hemochron® ACT and Sonoclot® ACT devices. Despite 
having comparable accuracy, both were equally and significantly affected by 
haemodilution and aprotinin.(15) Despotis et al. demonstrated anticoagulation 
management during CPB with the Hepcon® device to be more reliable than the 
standard ACT device.(17) The great variability in the ACT results showed it to be 
insensitive to detect incomplete heparin reversal, inadequate to detect low levels of 
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heparin or the heparin rebound phenomenon. Reasons for this, once again are related 
to hypothermia and haemodilution so commonly experienced during CPB, as well as 
the presence of aprotinin or glycoprotein IIa/IIIb inhibitors. The poor correlation 
between ACT and plasma heparin concentration during CPB is also evident in infants 
<6 months. Guzetta et al. compared three commercially available ACT instruments to 
bedside and laboratory plasma heparin concentrations. They concluded that sole 
reliance of the ACT test is not advisable.(18)   Galeone and colleagues also illustrated 
a poor correlation of ACT values to plasma heparin concentration, and hence, inability 
to detect residual heparin. In contrast, TEG® analysis showed significant association 
with plasma heparin concentrations, despite the exact relationship between the kaolin-
heparinase R time difference not being published.(1)  
 
Despotis evaluated the impact of heparin and protamine administration, guided by 
eiether ACT or ACT and whole blood heparin concentrations. While the protamine 
dose was similar in the two groups, the protamine: heparin ratio, the amounts of 
clotting factors and blood administered was less in the patients monitored with both 
ACT and heparin concentrations. 
 
 In summary, evidence shows that ACT may be a poor guide to heparin reversal for 
the attending anaesthesiologist. This may have risks with respect to post-operative 
bleeding.  
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Thromboelastogram (TEG®) and Thromboelstometry (ROTEM®) 
 The thromboelastogram (TEG®) and thromboelastometry (ROTEM®) are POC tests 
measuring whole blood visco-elastic properties allowing for more dynamic information 
regarding the coagulation process. Information regarding initiation and formation of 
the clot, the strength thereof, coagulation factor interaction and their interaction with 
platelets, platelet function and fibrinolysis is obtained within a short period of time.  The 
R-time (reaction time) can be available within 4-8 minutes and further information 
regarding clot kinetics within 10-20 minutes. The rapid availability of such useful 
information is appealing during and after CPB. Laboratory tests (platelet count, 
prothrombin time, activated partial thromboplastin time and fibrinogen levels) are not 
only unable to provide information on clot kinetics, but also have a much greater delay 
between sampling and obtaining the results.(19) 
 
Hartert introduced the concept of TEG in 1948, but it was only in 1996 that two different 
companies refined the method. TEG® is a registered trademark for the Haemoscope 
Corporation (USA) while ROTEM® is registered with Pentapharm GmbH (Germany). 
The physical principles of these two devices are comparable. The TEG® utilizes a pin 
attached to a torsion wire that is suspended in a blood sample in an oscillating cuvette. 
As the clot in the sample is formed, displacement of the pin occurs and is graphically 
depicted. ROTEM®, alternatively uses a stationary cup with the pin oscillating, 
transmission is via an optical sensor to a computer.(19) 
 
Nomenclature in the quantitative information differs between the two devices but is 
comparable. Reference ranges however differ due to variations in cup size, material 
of cup and the different activators (Table 3). The attending anaesthesiologist must 
therefore be familiar with the device available in their institution.(19, 20) 
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Parameter 
 
Units Definition TEG® ROTEM® 
Clotting time 
 
 
Clot kinetics 
 
 
Clot 
strengthening 
 
 
Amplitude 
Maximum 
strength 
Lysis 
s 
 
 
s 
 
 
deg 
 
 
 
mm 
 
Period from 0 to 
2mm amplitude 
 
Period from 2 to 
22mm amplitude 
 
Slope between r 
and k/slope of 
tangent at 2mm 
amplitude 
 
 
Maximal amplitude 
Reaction Time R 
 
 
Kinetics K 
Time 
 
α 
 
 
 
A 
Maximum 
amplitude 
MA 
CL 30, CL 60 
Clotting time CT 
 
 
Clot formation 
CFT 
 
α 
 
 
 
A 
Maximum clot 
Firmness MCF 
LY 30, LY 60 
 
 
Table 3. – TEG® and ROTEM® variables 
 
 
Test 
 
Activator/inhibitor User/indication 
Native 
 
Kaolin 
 
 
Heparinase 
 
Platelet 
mapping 
None 
 
Kaolin 
 
 
Kaolin and 
heparinase 
 
Adenosine 
diphosphate 
arachidonic acid 
Non-activated assay 
 
General coagulation assessment including 
platelet function 
 
Detection of heparin 
 
Platelet function monitoring during anti-
platelet therapy 
 
 
Table 4. – Commercially available TEG® assays 
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Test 
 
Activator/inhibitor User/indication 
na-TEM 
 
ex-TEM 
 
 
in-TEM 
 
 
fib-TEM 
 
 
ap-TEM 
 
 
Hep-TEM 
 
 
eca-TEM 
 
None 
 
Tissue factor TF 
 
 
Contact activator 
 
 
Tissue factor and 
platelet antagonist 
 
Tissue factor + 
Aprotinin 
 
Contract activator 
and heparinase 
 
Ecarin 
Non-activated assay 
 
Extrinsic pathway; fast assessment of clot 
formation and fibrinolysis 
 
Intrinsic pathway; assessment of clot 
formation and fibrin polymerization 
 
Fibrinogen level 
 
 
Fibrinolytic pathway; quick detection of 
fibrinolysis when combined with ex-TEM 
 
Detection of heparin 
 
 
Monitoring direct thrombin inhibitors (e.g., 
hirudin, argatroban) 
 
Table 5. – Commercially available ROTEM® assays 
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BISCHOF THROMBELASTOGRAPHY
132 MINERVA ANESTESIOLOGICA February 2010
formed in plasma at a temperature of 37 °C and
not in whole blood at the patient’s body temper-
ature.
In order to overcome these limitations, differ-
ent bedside coagulation monitoring methods are
available today, thrombelastography and thrombe-
lastometry being the most-widely used.4, 5
The aim of this article is to review the two tech-
niques, emphasizing their shared features but also
their differences. Moreover, an overview of their use
in different fields of application is provided.
Thrombelastography versus
thrombelastometry
Thrombelastography was introduced by Hartert
in 1948 6 as a method to monitor the clot devel-
opment in whole blood by assessment of its vis-
co-elastic properties, displaying fibrin formation,
clot strengthening and clot destruction (i.e., clot
lysis). Subsequently, this technique was refined by
two different companies, and, in 1996, thrombe-
lastograph and TEG® became a registered trade-
mark for the Haemoscope Corporation (Niles, IL,
USA). Therefore, these terms designate only tests
performed by Haemoscope devices and the com-
petitor Pentapharm GmbH (Munich, Germany),
describes the technique as rotation thrombelas-
tography (ROTEM®). 
However, their working principles are similar.
Both are based on the registration of the visco-
elastic properties of a blood sample by measuring
the mechanical impedance and the related changes
during clot formation. The TEG® device uses an
oscillating cup holding the blood sample while a
pin is suspended in the sample by a torsion wire.
During clot formation, the magnitude of the pin
movement and therefore of the torsion diminish-
es. This mechanical impedance change is trans-
formed by a mechanical-electrical transducer. The
ROTEM® technique, on the other hand, uses a
stationary cup and a pin oscillating in the cup.
The alteration of its movement as a result of clot
development is transmitted via an optical sensor to
a computer. 
After processing these signals, both devices dis-
play similar tracings (Figures 1, 2) and provide
quantitative information on the coagulation
process. Time of initial fibrin formation (TEG®:
reaction time = R vs. ROTEM® clotting time =
CT), fibrin formation kinetics and clot develop-
ment (TEG® kinetics = K and alpha angle = α vs.
ROTEM® clot formation time = CFT and alpha
angle = α, the final clot strength and stability
(TEG® maximum amplitude = MA vs. ROTEM®
maximum clot firmness = MCF) and fibrinolysis
(Table I).7-9 Despite the fact that both devices rep-
resent the same process, the reference values are
different. These findings may be explained by vari-
ations of cup size or material of the cup, but also by
differences of the coagulation activators, and have
to be considered when using algorithms developed
with one system while analyzing blood samples
with the other device.10 In order to improve the
ability to differentiate between coagulopathies of
different etiologies in a special clinical setting, dif-
ferent commercially available tests have been devel-
oped for each device (Tables II, III). The measure-
ment reproducibility of both devices are compa-
rable and are in a clinically acceptable range.11, 12
Figure 1.—Thrombelastography (TEG®) tracing. α: alpha angle;
CL: clot lysis; K: kinetics; MA: maximum amplitude; R: reaction
time.
Figure 2.—Thrombelastometry (ROTEM®) tracing. α: alpha
angle; CFT: clot formation time; CT: clotting time; LY: clot
lysis; MCF: maximum clot firmness.
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The R-time (reaction time) illustrates the time taken for initial clot formation. The effect 
of heparin in a sample will affect the R time on the TEG®. Other parameters, namely 
K-time, maximal amplitude (MA) and clot lysis remain unchanged.(1) 
 
An enzyme obtained from “flaviobacterium heparinum” called heparinase, may be 
added to the cuvette. This specifically cleaves the polysaccharide portion of heparin, 
eliminating the effect of heparin in the sample. This allows for the detection of non-
heparin haemostatic problems should they exist.(1) If the R-k time is prolonged, one 
would consider coagulation factor dysfunction; however, if this value has normalized 
after the addition of heparinase (R-heparinase time) the diagnosis of residual heparin 
can be made. Heparinase will not affect TEG variables of whole blood that do not 
contain heparin.(21) Nielsen, in an experiment using rabbits receiving stepwise 
heparin doses, found the TEG® to be more sensitive to changes in heparin activity 
than aPTT and ACT tests.(22)  
 
Implementation of protocols guiding blood and blood product transfusions based on 
TEG® or ROTEM® have successfully demonstrated a decrease in requirements in 
adults and children undergoing cardiac surgery.(6, 23-25) It is of great importance for 
us that such an approach creates significantly greater cost efficiency. Furthermore, 
TEG® and ROTEM® share moderate agreement regarding indications for 
transfusion.(26) Shore-Lesserson et al. performed a randomized control trial. 
Comparing conventional to TEG®-based algorithms to guide blood and blood product 
transfusion management during CPB. Despite no significant difference in mediastinal 
tube drainage between the 2 groups, there was clinically significant less use of blood 
and blood product therapy in the TEG®-based group.(23). Royston and von Kier 
published similar results (Figure 3).(25) 
 
Essell found the sensitivity of predicting blood loss to be similar between bleeding 
time, platelet count and TEG®, but TEG® to be the most specific. Furthermore they 
recommend that patients with an abnormal TEG® are at an increased risk of bleeding 
but that clinically excessive bleeding in the face of a normal TEG® implies surgical 
bleeding and that FFP and platelets should not be used empirically but attended to 
surgically.(27) 
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Subsequently, guidelines published in 2007 by the Society of Thoracic Surgeons and 
the Society of Cardiovascular Anaesthesiologists recommended the use of TEG® or 
ROTEM® to guide transfusion therapy.(28) 
 
Limitations of the TEG®/ROTEM® include that trained personnel are required to 
perform the test. Correct device maintenance must be adhered to. Blood sampling and 
storage (native or citrated samples) may affect the test result. Native blood 
demonstrates less variability compared to citrated blood but should be used within 4-
6 minutes. Citrated blood samples are stable for between 30 minutes to 2 hours for 
TEG® and for up to 6 hours for ROTEM®.(29, 30) Re-calcification before analysis is 
needed should citrated blood be used. Despite agreement with respect to identification 
of clotting and requirements for blood and factor usage, TEG® and ROTEM® 
parameters cannot be used interchangeably.(19) Finally, TEG® has never undergone 
all the validation procedures mandatory for conventional. Haemostatic tests such as 
intra- and inter-observer variability, repeatability, calibrations and quality controls.(31)  
 
Despite the limitations, TEG®/ROTEM® does permit trace detection of residual 
heparin and can hence guide heparin reversal with protamine after CPB.(19) The 
available studies on the subject will now be reviewed. 
 
Mittermayr challenged the routine use of ACT to confirm adequate reversal of heparin 
during CPB. Their institution, similarly to ours, uses a fixed dose of protamine 
calculated from the effective heparin dose. Adequate reversal thereof is then 
confirmed 15 minutes later with an ACT. Informed consent from 22 consecutive 
patients undergoing aorta-coronary bypass graft surgery was evaluated. Using the 
ROTEM® to detect adequate reversal rather than ACT. Their findings showed 
correlation of the ROTEM® (CT time) to heparin levels, regardless of haemodilution.  
 
Galeone and colleagues similarly demonstrated that ACT, R-kaolin time TEG®, and 
the difference between R-kaolin and R-kaolin heparinase TEG® correlated well with 
plasma heparin concentrations. However, subsequent multivariate analysis indicated 
that only the TEG® tests correlated significantly with plasma heparin concentration  
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(p<0,05) whereas ACT showed no correlation with plasma heparin concentration in 
both models.(1) 
 
Recently, our institution published a single centre, blinded prospective study 
comparing two POC tests as endpoints of protamine titration during CPB surgery. For 
this purpose, 82 adult patients undergoing CPB with relevant exclusion criteria were 
randomized into a TEG and ACT management group. The hypothesis stated that 
heparinase kaolin thromboelastogram (TEG-HK) R time difference would reveal the 
need for additional protamine doses compared to if ACT alone was used. The results 
revealed no such difference and the hypothesis was rejected.(32) The study displayed 
good power and adequate quality control. The shortcomings were thus attributed to 
the following: 
1) The initial dose of protamine to heparin ratio was relatively large (1,3:1 mg/mg).  
2) The protamine dose was based on the initial effective dose of heparin and 
neglected possible metabolism thereof. 
3) The endpoint of protamine titration in the ACT group was return to baseline ACT 
within 10%. However in the TEG group the range was not as strict and required a 
return to baseline within 20%. This had initially thought to be acceptable but later 
revealed a baseline of 10% should have been employed. 
4) When comparing POC tests, the gold standard of plasma heparin concentration 
should be measured and compared accordingly.  
.   
 
Protamine sulphate 
Protamine sulphate, a derivative of salmon sperm, is used to neutralise the 
anticoagulant effect of heparin. Positively charged molecules form ionic complexes 
with the negative charges of heparin in a 1:1 ratio. The elimination half-life is 20-30 
minutes. Side effects in the normal dose range (1-1,5 mg protamine per 100 IU 
heparin) include hypotension, decreased cardiac output, peripheral vasodilatation, 
bradycardia, potentially life-threatening pulmonary vasoconstriction and anaphylaxis. 
It has been demonstrated that protamine is toxic to the endothelium and the cardiac 
myocytes.(33). Proposed mechanisms to explain this include direct vasodilatation, 
depressed cardiac function,(34) histamine release and complement activation.(35) 
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Higher doses may contribute to bleeding during or post CPB.(36) Unbound protamine 
inhibits platelet activation, adhesion and aggregation.(37, 38)  Ratios greater than 
1,5:1 contributed to platelet dysfunction.(39) Furthermore, significant increase in the 
ACT is observed when ratios are above 2,6:1.(38) 
 
The fixed dose ratio method used to calculate the dose of protamine ignores the 
proportion of the initial dose of heparin that may have been metabolized. This explains 
why ratios as low as 0,8:1 has been reported to provide adequate reversal. Reductions 
in these ratios have been shown to decrease postoperative bleeding as well as 
reduced blood and blood product transfusions.(17).  Shigeta and colleagues used a 
titration method that adequately restored coagulation, preserved platelet response to 
thrombin and attenuated platelet alpha granule secretion during neutralisation. In their 
study, protamine doses in the titration group were less than half the doses in the fixed 
dose control group with no signs of heparin rebound or increased bleeding and hence 
adequate reversal.(40) This study therefore matched protamine administration to the 
amount of circulating heparin very effectively. The advantage to this method was a 
reduction in both protamine dose and potential toxicity. However, the clinician must be 
aware of a potential heparin rebound effect and subsequent bleeding.  
Rationale 
The use of POC tests has shown to reduce blood and blood product transfusion 
therapies (Figure 3). Therefore a goal directed algorithm guides the anaesthesiologist 
to make informed decisions. This may alleviate the deleterious effects of transfusion 
therapy as well as the cost burden of such therapies.(6) Empiric or prophylactic 
administration of transfusion therapy during CPB should not be entertained, neither 
the use of an insensitive or flawed monitor. Hence the POC test chosen to make such 
decisions should be as accurate as possible and comparable to the gold standard, in 
our proposed study, the focus will be on identifying the sensitivity of a particular POC 
test to heparin concentrations.  
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Figure 3. The impact of use of an algorithm coupled to POC monitoring with 
respect to mean total donor exposures observed in eight published studies. 
Hatched bar represents the mean total donor exposures within the control group 
(C) whereas the solid bar represents the mean total donor exposures within the 
group of patients who were treated with an algorithm coupled to point-of-care 
monitoring (M) perioperatively. Asterisks represent P < 0.05 between treatment 
cohorts. (41) 
 
Every day Tygerberg hospital facilitates life saving surgery in the cardiothoracic 
theatres. A dedicated and highly specialized team of nurses and doctors focus on 
delivering the highest quality of medical and surgical care possible, making use of their 
knowledge as well as the resources available at their disposal. The attending 
anaesthesiologist makes critical decisions during and after cardio-pulmonary bypass, 
including the adequacy of the reversal of heparin. As previously mentioned, evidence 
indicates ACT to be an unreliable marker for heparin reversal. Regardless of this, 
clinical practice still largely makes use of this POC test. The TEG® has substantial 
evidence supporting the device as a POC test to guide and facilitate optimal decision 
making for coagulation monitoring. In this respect, a difference in R-time between a 
kaolin and heparinase TEG® implies that residual heparin is present in the blood. 
However, the exact relationship between the quantity of heparin that remains and the 
R time difference is not known. We wish to study the relationship between these 
variables. This is novel research and little if any precise data on this topic is currently 
available. 
marized in Table 2. Although excessive bleeding after cardiac
surgery can be related to reduced circulating levels of coagu-
lation factors [3] and other abnormalities such as heparin
rebound, hypothermia and/or acidosis [2], platelet-related
abnormalities listed in Table 2 are considered the most
important hemostatic abnormality in this setting.
Although the use of aspirin and non-steroidal anti-
inflammatory agents can lead to bleeding in a subset of
patients who display evidence of an exaggerated response to
these agents (i.e. hyper-responders), the majority of patients
do not bleed excessively because the majority of patients
manifest a normal response to aspirin (i.e. mild platelet
inhibition) [4]. Similarly, although patients on preoperative
warfarin may bleed after cardiac surgery, two studies have
demonstrated an inverse relationship between postoperative
International Normalized Ratio (INR) and blood loss,
which may be secondary to warfarin-mediated hemostatic
system-preservation during CPB. The introduction and use
of lower molecular-weight heparin compounds, direct inhib-
itors of thrombin (e.g. hirudin, argatroban, bivalirudin,
dermatan, Orgaran), and platelets (e.g. abciximab, eptifiba-
tide, tirofiban and most importantly long-acting adenosine
diphosphate (ADP) antagonists such as clopidogrel [2]) as
well as fibrinolytic agents (e.g. recombinant tissue plasmin-
ogen activator) can potentially increase bleeding and com-
plicate clinical management. The risk of bleeding related to
these agents depends on their relative potency, pharmacody-
namic half-life, time-interval from most recent dose before
surgery, and whether or not a reversal agent is available.
Although, the exact association between these agents and either
the severity of bleeding or transfusion requirements in patients
undergoing cardiac surgical procedures is evolving, several
reports have demonstrated severe, intractable bleeding with use
of either the direct thrombin inhibitors for anticoagulation with
CPB or with preoperative use of clopidogrel [2].
Management of bleeding
Hemostatic blood components: therapy and dosing
Traditional management of excessive bleeding has involved
intravenous administration of hemostatic-augmenting phar-
macologic agents or hemostatic blood components. Replen-
ishment of coagulation factors can be achieved either with the
use of fresh-frozen plasma (FFP), cryoprecipitate or factor
concentrates. Both National Institutes of Health (NIH) [5] and
American Association of Anesthesiologists (ASA) [6] guideline
recommendations for the use of FFP in the perioperative
setting have previously been published [5]. The ASA guidelines
recommend that FFP be used in the setting of active bleeding
that may be related to substantial reductions in coagulation
factor levels (i.e. prothrombin time (PT) and activated partial
thromboplastin time (APTT) > 1.5· the mean value of a
normal reference population) [6]. Approximately 15 mL kg)1
of FFP will result in a rise in factor values by 30%
(i.e. 0.3 U mL)1) in the average adult. Cryoprecipitate is
generally administered for either hypofibrinogenemia (<80–
100 mg dL)1) or dysfibrinogenemia. Approximately 10 U of
cryoprecipitate will increase fibrinogen by 100 mg dL)1 and
administration of 15 mL kg)1 of FFP will increase fibrinogen
to nearly the same degree. With non-urgent requirements,
Vitamin K can be administered to reverse the effects of
warfarin (i.e. reductions in factors II, VII, IX and X as well as
protein C and S) within 6–8 h after intravenous administration.
Similarly, NIH [7] and ASA [6] consensus panels have
suggested that platelets be administered in the following
settings; for active bleeding with thrombocytopenia (i.e.
platelets < 50 000 lL)1), when abnormal platelet function is
contributing to bleeding or for prophylaxis with a platelet
count <20 000 lL)1 in patients at high risk of bleeding [7].
Platelets should be administered with massive blood transfu-
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The motive to undertake this research is to better define the endpoint of reversal of 
heparin with protamine. This is important for many reasons. It may reduce 
postoperative coagulopathy with all the implications on blood and blood product usage 
and need for surgical re-exploration. Meticulous protamine dosing is critical to the 
patient and eliminates unwanted and harmful side effects.  
 
 
Hypothesis 
 
Null Hypothesis: The difference between the R-times of kaolin and heparinase 
TEG® is not able to predict residual heparin activity after in vitro protamine titration. 
 
Alternate Hypothesis: The difference between the R-times of kaolin and 
heparinase TEG® is able to predict residual heparin activity after in vitro protamine 
titration. 
 
Primary outcome 
The relationship between the TEG® R time difference and heparin activity-
concentrations. 
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Methods 
Study design and target population 
1. This will be a single centre, prospective, randomized, laboratory study.  
2. The study population will consist of patients undergoing cardiac surgery at 
Tygerberg Hospital who will be heparinised while on cardiopulmonary bypass. 
3. 20 patients will be required. 3 samples of 1o ml of blood will be taken per patient. 
Thus a total of 60 samples (20 patients x 3 samples) and a total of 30 ml of blood 
per patient ( 3 x 10 ml blood samples).  
Inclusion criteria  
Patients will be eligible for enrolment in this study if they meet the following criteria: 
1. Elective or emergent cardiac surgery at Tygerberg Hospital. 
2. Coronary artery bypass surgery or valve replacement procedures, or both 
combined. 
3. On-pump coronary artery bypass surgery. 
4. Patients who will be and are, heparinised for cardiopulmonary bypass. 
5. Patients on low dose aspirin up to 150 mg daily including administration on the day 
of surgery. 
6. Patients on intravenous heparin before surgery. 
7. Adults exceeding 18 years of age and exceeding 45 kg body weight. 
Exclusion criteria 
Patients will not be eligible for enrolment in this study if they meet the following 
criteria: 
1. Patients less than 18 years of age and less than 45kg in weight.  
2. Patients scheduled to have off-pump surgery. 
3. Pre-existing, known or suspected coagulopathy or administration of anticoagulants 
such as: 
3.1. Confirmed or suspected antithombin 3 deficiencies 
3.2. Low molecular weight heparin in the 48 hours prior to surgery 
3.3. Known protein S and/or protein C deficiency 
3.4. Other known pre-existing coagulation defects, acquired or congenital. 
3.5. Antiplatelet agents other than low dose cardiac aspirin in the last week before 
surgery 
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3.6. Anticoagulants other than heparin preoperatively in the last 2 weeks before 
surgery 
3.7. Hepatic dysfunction affecting synthesis of coagulation factors with international 
normalised ratio exceeding 1.5 
3.8. Renal dysfunction with urea or creatinine exceeding 15 mmol/l and 300 umol/l 
respectively. 
Patient preparation 
1. The normal preparation for a patient undergoing cardiac surgery will be followed. 
This study places no demands on the anaesthesiologist or changes in practice at 
all.  
2. The anaesthetic technique will be left to the discretion of the anaesthesiologist.  
3. The dose of heparin administered will also be left to the discretion of the 
anaesthesiologist and the perfusionist.  
Data collection 
The relevant data will be noted on a purposely-designed data collection form as 
specified in Appendix A. The following data will be collected:  
1. Patient demographics; patient weight, length, gender, INR, PTT, platelet count, 
urea, creatinine, recent anticoagulants and procedure to be  performed.  
2. Haemoglobin concentration as measured by blood gas machine within the last 20 
minutes 
3. Volume of Balsol added to pump 
4. R times of TEG-k and TEG-kh 
Randomization 
The samples will be randomized according to a scheme worked out on the website 
www.randomization.com for the following ratios of protamine: heparin ratios: 0.25, 
0.5:1 and 0.75:1. (Appendix B) 
Sampling and performance of TEG®  
1.  Each patient will have 3 samples of blood taken during CPB. Each sample will 
contain 10 ml of blood. Thus, a total of 30 ml per patient (3 x10 ml) 
2.  10 ml of blood taken from CPB circuit arterial-venous reservoir bypass in a new 20 
ml plastic syringe.  
3.   Protamine will be added, undiluted using an insulin syringe, to the 10 ml sample 
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containing the blood drawn via the bypass machine. The protamine dose will be 
randomised according to the scheme above. The exact protamine dose will be 
calculated according to patient weight, gender, and total heparin dose 
administered to the patient using a spreadsheet created specifically for this 
purpose. The calculations are as follows: 
3.1.  Estimated blood volume = blood volume (ml/kg) x body weight (kg) where 
estimated blood volume is considered to be 65 and 75 ml/kg for females and 
males respectively. 
3.2. Protamine dose to be added to the 10 ml blood sample (mg) = (Protamine: 
heparin ratio (mg/mg) x total dose of heparin administered to patient (mg)) x 
(10 ml/estimated blood volume  (ml)). The protamine: heparin ratio will be 
determined from the randomization scheme. 
4.   1 ml of air will be drawn into the 10 ml blood sample containing the protamine and 
blood mixture, this syringe will be inverted 4 times to ensure complete mixing of 
the protamine and the blood. 
5. Blood will be withdrawn from the 10 ml blood sample for performance of the kaolin 
and kaolin-heparinase TEG® by the technologists trained to perform this test using 
a similar standardised procedure.  We will conduct a quality control to ensure that 
the two operators produce comparable TEG® results. Acceptable reproducibility is 
defined as being able to conduct 3 sets of tests with less than a 10% difference 
between parameters. The biweekly TEG® quality control will be meticulously 
performed. 
6.   The time frame for drawing of the blood, adding protamine, performing the TEG® 
and adding the sample to the citrated tube will be a maximum of four minutes.   
7. The TEG® will be stopped after the R-times have developed and been noted. 
These R-times will be noted down on the data sheet, and a printout hereof will also 
be kept. 
Determination of Heparin levels   
1. 4,5 ml of the blood sample to which protamine has been added will be added to a 
labelled, citrated test tube for analysis of heparin activity.  
2. The sample tubes will be placed on ice and immediately be taken to the coagulation 
laboratory, where they will be centrifuged and the plasma stored at -80 degrees 
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Celsius. Heparin is stable at this temperature. Heparin assay will be performed in 
batches. Heparin levels will be measured using a modified anti-Xa chromogenic 
assay, the current gold standard method of heparin level determination. 
Data management 
1. Intra operative data will be collected on a predetermined data sheet. (Appendix A) 
The data will be de-identified so that no data that can directly identify any patient. 
2. The data will be entered into a Microsoft Excel® spreadsheet for processing and 
thereafter, statistical analysis. 
Sample size 
1. Prof Johan F Coetzee of the Department of Anaesthesiology and Critical Care has 
been consulted regarding study design, power and statistical analysis. 
2. If a linear relationship is assumed between parameters, the regression equation 
will be one of a straight line, i.e. y = bx + c, where y is the dependent variable 
(heparin activity) and x is the independent variable (R time difference).   Using the 
procedure for linear regression in the PASS software, the following result was 
obtained, assuming the following:  
2.1. Standard deviation of the x values 0, 0.5, 1.0, 1.5 (standard deviation 0.56) 
(i.e. using fractional values rather than percentages) 
2.2. That you would require a power of 0.95 
2.3. Two sided alpha 0.05 
2.4. A slope of at least 0.5 
2.5.  A Pearson’s product moment correlation coefficient (r) between x and y of at 
least 0.5.   
3. In summary, a sample size calculation for linear regression revealed that a sample 
size of at least 42 samples is required to detect with 95%  power the following 
relationship: A slope of 0.5 and a Pearson’s product moment correlation coefficient 
of 0.5 with a two sided alpha value of 0.05 assuming a standard deviation of the R 
time differences of 56%. 
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3.1. As this is a pilot study, we wish to increase the sample size by approximately 
50% to 60 samples to ensure that we do not incur a beta error should our 
sample size be estimations be somewhat incorrect.  
Statistical analysis 
1. Data will be analysed using Medcalc® for Windows. 
2. The data will first be analysed for normality of distribution and equality of variance 
using the Kolmogorov Smirnov and Levene Median tests respectively.   
3. Parametric data that is normally distributed will be analysed using a two-tailed two-
sample t test. Data will be presented as mean, standard deviation and 95% 
confidence interval of the difference between the means. Nonparametric data and 
data that is not normally distributed will be analysed using the Mann Whitney Rank 
Sum test. Data will be presented as median, 25 and 75th percentiles. Nominal and 
ordinal data will be analysed using Chi squared tests. 
4. The relationships between the TEG® R-time difference and the heparin 
concentrations will be analysed depending on whether the data is normally 
distributed or not using Pearson or Spearman’s rank coefficient tests. The 
mathematical relationship describing the best fit between the parameters will be 
determined using Excel®. 
5. A p value of < 0.05 will be accepted to represents a statistically significant 
difference between parameters. 
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Ethical considerations 
1. There are no risks for the patient. The main risk would be of us performing the 
study incorrectly and/or making incorrect conclusions from the study. 
2.  Blood sample volumes will comprise only 10 ml specimens at a time. 3 samples 
per patient. 
3.  Patients enrolled will be those who are scheduled to be administered heparin on 
cardiopulmonary bypass. 
4.  The population studied could be considered vulnerable, but we managed them 
ethically. Informed consent will be obtained. 
5.  The study population consists of patients undergoing elective cardiac surgery at 
Tygerberg Hospital 
6. The study population will thus be fairly chosen, and will not be exposed to any 
additional risks. 
7. From an ethical point of view, we are of the opinion that this study is sound. Patient 
autonomy will be respected through proper consent prior to enrolment of all 
participants. The study will take place in vitro and no new interventions are to be 
undertaken, and it will not influence the patient’s management in any way. The aim 
of this study is to equip doctors to more easily have an endpoint of heparin reversal, 
which would imply better, and more scientific, patient care with less risk involved 
after the study. 
8. This research study will be submitted for approval by the Health Research Ethics 
Committee (HREC) at the University of Stellenbosch and will be done according to 
internationally accepted ethical standards and guidelines. 
9.  Informed consent will be obtained from patients with the use of attached forms for 
this purpose. (See Appendix C) 
10. A consecutive number will be assigned to each patient and data capture and 
presentation will be performed with these numbers. Patient privacy and 
confidentiality will thus be protected. 
11.  Participants have the right to withdraw from the study at any time. 
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Potential strengths of the study 
1. There are no risks for the patient. The main risk would be of us performing the 
study incorrectly and/or making incorrect conclusions from the study. 
2. The volume of blood removed from the patient is relatively small, the 30 ml 
representing less than approximately 0,45% of the blood volume on 
cardiopulmonary bypass of a typical 70 kg patient. This should not affect 
transfusion requirements or anaemia postoperatively. 
3. Even if small errors are made in the dose of protamine, this will not matter; it is not 
the dose of either protamine or heparin that matters but the relationship between 
the TEG® R-time difference and the residual heparin concentrations that we wish 
to determine. Thus scatter of the data will be of value to determine the relationship. 
4. Blood from patients on bypass will be used to perform this study: this ensures that 
any factors present during cardiopulmonary bypass that will affect the coagulation 
will be reflected by the TEG®. This study represents reality as closely as possible 
without changing practice. The heparin concentrations are also clinically relevant. 
This study could be performed by heparinising blood drawn form volunteers, then 
performing all the manipulations described above. However, whether this can be 
done in the requisite time (4 minutes) is not clear. The potential effects of release 
of tissue factor VII and venous stasis during venipuncture is also eliminated with 
the study design chosen. The difficulties of attempting to achieve typical 
heparinisation of blood are also eliminated when using this study design. 
5. We have experience in this field having published before. 
6. We have experienced technologists who perform TEG® to a high standard in a 
dedicated laboratory on a calibrated, well-maintained machine.  
7. Our laboratory has previous experience in measuring heparin concentrations. 
8. Envisaged outputs of this study include attainment of a Masters degree in 
Anaesthesiology and Fellowship in the College of Anaesthesiology (FCA) 
specialist degree. This aids student training. If at all suitable, it will be considered 
for publication.  
Potential limitations of the study 
1. We are not performing this study after administration of protamine to patients after 
bypass. While this would be ideal, we foresee that there would be significant 
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clumping of the data, making definition of the relationship between TEG® R-time 
difference and heparin concentrations difficult to define with accuracy.  
2. We could perform this study by giving the protamine fractionally and then 
determining the relationship between TEG® R-time difference and heparin 
concentrations. This may have more risks for the patient as this alters clinical 
practice significantly, is not representative of clinical practice, puts the patient at 
risk of significant bleeding and would prolong surgery significantly. 
3. It is an in vitro study that does not follow clinical practice exactly. 
 
Timeframes 
1. Timeframe for collection of samples: It is estimated that 3 patients per week will 
qualify for enrolment, and if a total of 20 patients are required, data collection 
should take between 6 to 8 weeks. 
2. Timeframe for sample processing: The measurement of heparin concentrations 
will be processed as a batch. This will take approximately one to two months, 
depending on if this occurs over the December /January period. 
3. Processing of samples and data capturing:  2 months 
4. Data analysis: This will take 1 to 2 months 
5. Timeframe for writing up and discussing results: 12 months. This is an 
important part of the process and we wish to be thorough in this regard; it also 
usually takes longer than expected. 
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Costs and funding  
1. Application to the Harry Crossley Foundation for funds has been made and 
granted. 
2. Cepheid will sponsor a second TEG® device for the duration of the study. 
 
 
 
Summary of the protocol 
 
Sample blood from patient on CPB 
 
 
 
   Add protamine to sample, use sample for  
      
 
 
  TEG®     Heparin concentration in blood 
(kaolin and heparinase)   (anti Xa assay in lab) 
 
 
 Discern relationship between parameters 
 
CONSUMABLES  
Syringes and needles:  R 200 
TEG® consumables: R150 x 126  R18 900 
Determination of heparin concentrations: R 600 x 63 R 37 800 
Protamine: R 50 x 12 ampoules R 600 
Total costs R 57 500 
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Appendix A: Data Collection form 
 
TEG [Kaolin versus Heparinase] R-time difference to predict heparin activity 
Date  
Time 
Sample number according to randomization 
Protamine dose according to spread sheet calculator 
Patient demographics  
Weight 
Length 
Gender 
INR preoperative  
PTT 
Platelet count preoperative  
Urea  preoperative 
Creatinine preoperative  
Preoperative anticoagulants  
Procedure to be  performed 
Intraoperative data: 
Heparin dose administered total intraoperatively 
Hemoglobin concentration within the last 20 minutes 
Most recent ACT within the last 20 minutes 
Volume of Balsol added to pump 
Coagulation data: 
R time TEG-Heparinase 
R time TEG-Kaolin 
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Appendix B: Randomization schedule 
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Appendix C: Informed consent 
 
[Please note that we have excluded randomization from the informed consent, as it 
has no bearing on the patient]. 
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Participant information leaflet and consent form 
Title of the research project: 
 
“The ability of the thromboelastogram (TEG®  R-
time difference between kaolin and heparinase) as a 
point of care test to predict residual heparin activity 
after in vitro protamine titration”. 
Reference number: 
Principal investigators: Dr L Joseph, Prof AI Levin 
Address: Department of Anesthesiology and Critical Care, University of Stellenbosch 
and Tygerberg Academic Hospital 
Contact number: 021-9389230 
 
You are being invited to take part in a research project.  Please take some time to read 
the information presented here, which will explain the details of this project.  Please 
ask the study staff or doctor any questions about any part of this project that you do 
not fully understand.  It is very important that you are fully satisfied that you clearly 
understand what this research entails and how you could be involved.  Also, your 
participation is entirely voluntary and you are free to decline to participate.  If you say 
no, this will not affect you negatively in any way whatsoever.  You are also free to 
withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee (HREC) at 
Stellenbosch University and will be conducted according to the ethical guidelines and 
principles of the International Declaration of Helsinki, South African Guidelines for 
Good Clinical Practice and the Medical Research Council (MRC) Ethical Guidelines 
for Research. 
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What is this research study all about? 
This study is about how good a test is to see the remaining amount of an anticlotting 
agent is after administration of an antidote. 
 
Where will this research project take place? 
It will take place in Tygerberg Hospital theatres.  There will be approximately 20 
participants. 
 
What is the aim of this research project? 
This experiment is designed to test how accurate the TEG® test is in predicting how 
much blood thinner (heparin) remains after surgery. 
 
The information obtained from this experiment will help us treat future patients more 
accurately.  
 
That is why we wish to do this study. 
 
Explain all the procedures. 
The procedures used during heart operations will be done as usual. 
 
Once you are on the heart lung machine, small samples of your blood will be taken 
from the machine. 
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The amount of blood is two teaspoons (ten millilitres) at 3 separate times. You have 
approximately 650 times this amount of blood in your body and your body will not 
notice this amount of blood removal. 
 
The experiments will be performed on your blood in test tubes outside your body. 
TEG® tests as well as direct measurement of blood thinner (heparin) will be done at 
the same time and the results compared. This will give us information about how 
accurate the TEG® test is.   
 
The experiment will be performed in a test-tube outside your body and therefore, there 
is no risk to you.   
 
Why have you been invited to participate?  
You are invited to participate in this study because you are undergoing cardiac 
surgery. 
 
What will your responsibilities be?  
You will not have to do anything additional, nor will you receive any treatment other 
than the treatment you would have received if you are not participating in the study. 
 
Will you benefit from taking part in this research?  
You personally will not benefit from the study, however future patients may benefit 
from the results of the study. 
 
Are there risks involved in your taking part in this research?  
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There are no additional known risks for your participation in this study, apart from the 
risks associated with the surgery itself as explained by the surgeon. 
 
If you do not agree to take part, what alternatives do you have?  
Whether you agree to participate in the study or not, you will receive the same 
treatment. 
 
Who will have access to your medical records?  
The information gained from the study is anonymous, and any information will be 
treated as confidential. If the information is used in a publication or thesis, your identity 
will not be revealed. The doctors conducting the study will have access to the 
information and will treat it as confidential. If anything of relevance to your health is 
noted, you will be informed thereof. The auditors or ethics committee members may 
need to inspect research records. 
 
What will happen in the unlikely event of some form injury occurring as a direct 
result of your taking part in this research study?  
As you are not receiving any treatment different from the standard care, there are no 
additional risks involved if you participate in the study. 
 
 
 
Will you be paid to take part in this study and are there any costs involved?  
No you will not be paid to take part in the study. There will be no costs involved for 
you, if you do take part. The Harry Crossley Fund has kindly funded the project. 
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Cepheid will also sponsor a second TEG® machine, allowing us to perform the 
laboratory tests. 
 
Is there anything else that you should know or do? 
You can contact Dr L Joseph at telephone 021-9385142 or Prof AI Levin at 021 
9389230 if you have any further queries or encounter any problems. 
 
You can contact the Health Research Ethics Committee at 021-938 9207 if you have 
any concerns or complaints that have not been adequately addressed by your study 
doctor. 
 
You will receive a copy of this information and consent form for your own records. 
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Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a 
research study entitled “The ability of the thromboelastogram (TEG®  R-time 
difference between kaolin and heparinase) as a point of care test to predict 
residual heparin activity after in vitro protamine titration”. 
 
 
I declare that: 
 
I have read or had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
I have had a chance to ask questions and all my questions have been adequately 
answered. 
 
I understand that taking part in this study is voluntary and I have not been pressurised 
to take part. 
I may choose to leave the study at any time and will not be penalised or prejudiced in 
any way. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 
2015. 
 
 
 
    
Signature of participant    Signature of witness 
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Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
I explained the information in this document to ………………………………….. 
 
I encouraged him/her to ask questions and took adequate time to answer them. 
 
I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above. 
 
I did/did not use a translator.  (If a translator is used then the translator must sign the 
declaration below. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 
2015. 
 
 
 
    
Signature of investigator    Signature of witness 
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Declaration by translator 
 
 
I (name) ……………………………………………..……… declare that: 
 
I assisted the investigator (name) ………………………………………. to explain the 
information in this document to (name of participant) 
……………..…………………………….. using the language medium of 
Afrikaans/Xhosa/other. 
 
We encouraged him/her to ask questions and took adequate time to answer them. 
I conveyed a factually correct version of what was related to me. 
 
I am satisfied that the participant fully understands the content of this informed consent 
document and has had all his/her question satisfactorily answered. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 
2015. 
 
 
 
    
Signature of translator    Signature of witness 
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Approval Notice
Response to Modifications- (New Application)
23-Jan-2015
Joseph, Lauren
Ethics Reference #: S14/10/247
Title: The ability of thromboelastogram (TEG R time difference between kaolin and heparinase) as a point of care test topredict residual heparin activity after in vitro protamine titration.
Dear Dr Lauren Joseph,
The Response to Modifications - (New Application) received on 05-Jan-2015, was reviewed by members of Health Research Ethics Committee 2
via Expedited review procedures on 20-Jan-2015 and was approved.
Please note the following information about your approved research protocol:
Protocol Approval Period: 23-Jan-2015 -23-Jan-2016
Please remember to use your protocol number (S14/10/247) on any documents or correspondence with the HREC concerning your research protocol.
Please note that the HREC has the prerogative and authority to ask further questions, seek additional information, require further modifications, or
monitor the conduct of your research and the consent process.
After Ethical Review:
Please note a template of the progress report is obtainable on www.sun.ac.za/rds and should be submitted to the Committee before the year has expired.
The Committee will then consider the continuation of the project for a further year (if necessary). Annually a number of projects may be selected
randomly for an external audit.
Translation of the consent document to the language applicable to the study participants should be submitted.
Federal Wide Assurance Number: 00001372
Institutional Review Board (IRB) Number: IRB0005239
The Health Research Ethics Committee complies with the SA National Health Act No.61 2003 as it pertains to health research and the United States
Code of Federal Regulations Title 45 Part 46. This committee abides by the ethical norms and principles for research, established by the Declaration of
Helsinki, the South African Medical Research Council Guidelines as well as the Guidelines for Ethical Research: Principles Structures and Processes
2004 (Department of Health).
Provincial and City of Cape Town Approval
Please note that for research at a primary or secondary healthcare facility permission must still be obtained from the relevant authorities (Western Cape
Department of Health and/or City Health) to conduct the research as stated in the protocol. Contact persons are Ms Claudette Abrahams at Western
Cape Department of Health (healthres@pgwc.gov.za Tel: +27 21 483 9907) and Dr Helene Visser at City Health (Helene.Visser@capetown.gov.za Tel:
+27 21 400 3981). Research that will be conducted at any tertiary academic institution requires approval from the relevant hospital manager. Ethics
approval is required BEFORE approval can be obtained from these health authorities.
We wish you the best as you conduct your research.
For standard HREC forms and documents please visit: www.sun.ac.za/rds
If you have any questions or need further assistance, please contact the HREC office at 219389207.
Included Documents:
Response to modifications: Cover letter
Response to modifications: MPS Cert A Levin
Application form
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Chapter 3: Article 
 
Abstract 
 
Background: The adequate reversal of heparin with protamine at the end of 
cardiopulmonary bypass (CPB) is critical. Despite a difference between 
thromboelastographic R-kaolin time and R-heparinase time (TEG® Delta-kh R-time) 
indicating residual heparin, their exact relationship is not known.  
Aims: We aimed to define the in-vitro relationship between (TEG® Delta-kh R-time) 
and plasma heparin concentrations. We also aimed to determine the concentrations 
of heparin at or below which R-kaolin times became measureable before a 90-minute 
cut-off. 
Methods: 
This was a single centre, prospective, randomized laboratory study. Samples were 
taken during CPB and randomized to a 0.25, 0.5, and 0.75 mg/mg protamine:heparin 
titration. This sample was subject to TEG® and heparin concentration analyses. 
Results: 
No relationships existed between R-kaolin times and heparin concentration (p=0.80) 
or between measurable TEG® Delta-kh R- time difference and heparin concentration 
(p=0.42). However, we did identify a high probability of being able to predict a 
measurable R-kaolin time (negative predictive value 90%, 95% CI 74% to 98%) with 
heparin concentrations < 1.24 IU/ml. 
Conclusions:  
We could not establish the relationship between the TEG® Delta-kh R-time difference 
and heparin concentrations probably due to flawed methodology. We speculated as 
to the reasons and suggest an alternative future methodology.  
 
However, the study did reveal unique, useful information that R-kaolin time will likely 
be measurable at heparin concentrations below 1.24 IU/ml, and vice versa. This 
observation is immensely valuable for the clinician and also for the researcher.  
 
Keywords: TEG, thromboelastography, heparin, cardiopulmonary bypass, protamine, 
bleeding, coagulopathy, activated clotting time, ACT 
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Introduction  
 
Postoperative bleeding is one of the main complications after surgery involving 
cardiopulmonary bypass (CPB); indeed this complication occurs in approximately 20% 
of patients.(1). Differentiation between surgical bleeding and coagulopathy is critical. 
Re-exploration for post-operative bleeding is associated with an increase in mortality 
and morbidity (2). A surgical cause is found in 50% of patients; therefore many re-
explorations can be avoided if a coagulopathy can be better identified and treated. 
These risks are further aggravated by the hazards, exorbitant cost and consequent 
intense scrutiny of the related transfusions that accompany postoperative bleeding. 
 
It is therefore critical to monitor coagulation during and after surgery involving CPB. 
Laboratory tests are of little value during and after CPB, this being largely due to their 
delay in results. Their role in the pre-operative setting is still useful with the activated 
partial thromboplastin time (aPTT) being sensitive to low concentration levels of 
heparin. Various point of care (POC) tests such as activated clotting time (ACT), 
thromboelastogram (TEG®) and rotational thromboelastometry (ROTEM®) are 
available for this purpose. POC tests are defined as diagnostic tests at or near the 
bedside with the ability to produce rapid results.(3). This may provide guidance for the 
attending anaesthesiologist to correctly diagnose the cause of bleeding.(4). 
Coagulation monitoring with thromboelastography has been shown to decrease 
transfusion therapy and hence an improvement in outcome and diminished costs 
overall.(5, 6) Indeed, compared to TEG®/ROTEM® guided therapy, empiric therapy 
with blood and blood products are of questionable efficacy and may be hazardous to 
the patient.(7) 
 
Apart from other causes of coagulopathy, it is of particular importance to monitor 
adequate heparinisation and conversely, heparin neutralisation with protamine. 
Meticulous dosing of protamine is required as excessive dosages of this drug has 
deleterious side effects on clotting and can aggravate bleeding. Individual responses 
to a dose of heparin vary. Individuals may exhibit heparin resistance and require a 
higher dose due to acquired or inherited antithrombin III deficiency or increased protein 
binding of heparin.(8). At the end of surgery, it is critical to ensure that no residual 
heparin remains, potentially exposing the patient to the risk of developing a 
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coagulopathy. This needs to be done in a timely manner and hence POC tests are 
ideal.  
The use of POC tests has shown to reduce blood and blood product transfusion 
therapies. Therefore, a goal directed algorithm guides the anaesthesiologist to make 
informed decisions. This may alleviate the deleterious effects of transfusion therapy 
as well as the cost burden of such therapies.(6) Empiric or prophylactic administration 
of transfusion therapy during CPB should not be entertained, neither the use of an 
insensitive or flawed monitor. Hence the POC test chosen to make such decisions 
should be as accurate as possible and comparable to the gold standard.  
 
A difference in R-time between a kaolin and heparinase TEG® implies that residual 
heparin is present in the blood. However, the exact relationship between the quantity 
of heparin that remains and the R-time difference is not known. We wanted to study 
the relationship between these variables.  
 
Methods 
 
Prior approval from the University of Stellenbosch Human Research Ethics Committee 
(HREC) was obtained, reference number S14/10/247. A single centre, prospective, 
randomized laboratory study was conducted at Tygerberg Hospital between 
September 2015 and December 2015. Prior informed consent was obtained from 
patients who were planned to undergo cardiac surgery using cardiopulmonary bypass 
(CPB).  
 
The null hypothesis was that the difference between the R-times of kaolin and 
heparinase TEG® is not able to predict residual heparin activity after in vitro protamine 
titration. The alternate hypothesis was that the difference between the R-times of 
kaolin and heparinase TEG® is able to predict residual heparin activity after in vitro 
protamine titration.  The primary endpoint was to determine the relationship between 
the difference in TEG® generated R-times (R-kaolin minus R-heparinase) and the 
heparin concentration.  The secondary outcome was to determine the concentrations 
of heparin at or below which R-kaolin times became measureable, or were at least 
below 90 minutes. 
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Inclusion criteria were adults exceeding 18 years of age and 45kg body weight that 
were scheduled for elective ± emergent valve replacement and/or coronary artery 
bypass grafting (CABG) using cardiopulmonary bypass. Patients on low dose aspirin 
(up to 150 mg daily), even if administered on the day of surgery, as well as patients 
on intravenous heparin before surgery, were included. Exclusion criteria comprised 
patients undergoing cardiac off-pump surgery, pre-existing or suspected 
coagulopathy, administration of low molecular weight heparin (LMWH) in the 48 hours 
prior to surgery, administration of  other antiplatelet agents within the two weeks prior 
to surgery and patients with hepatic dysfunction affecting synthesis of coagulation 
factors with international normalised ratio exceeding 1.5 as well as renal dysfunction 
with urea or creatinine exceeding 15 mmol/l and 300 umol/l respectively. 
 
Premedication, anaesthetic techniques, monitoring, and the heparin dose were solely 
at the discretion of the attending anaesthesiologists.  
Sampling and performance of TEG®  
 
 Each patient had three 10 ml blood samples taken from the CPB circuit, each sample 
being drawn with a new 20 ml plastic syringe. Protamine was added to each 10-ml 
blood sample. The required protamine dose was calculated using an Excel® 
spreadsheet that performed the following calculations: 
EBV = BV x weight 
Where, EBV= estimated blood volume in ml. BV = blood volume (ml/kg) where blood 
volume is considered to be 65 and 75 ml/kg for females and males respectively. 
Weight expressed as kg. 
P dose = !:# (%	'()*)(,-./)012  
 
Where, P dose is the protamine dose to be added to the 10 ml blood sample in mg,  
p:h is the protamine to heparin ratio expressed as mg/mg, and H dose is the total dose 
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of heparin administered to the patient (mg). Each blood sample was treated to one of 
three heparin: protamine ratios (0.25, 0.5, or 0.75 mg/mg) based on a randomization 
schedule from “www.randomization.com”. The protamine was added undiluted using 
an insulin syringe. After the specific protamine dose was established from the 
randomization schedule, ne ml of air was drawn into the 10 ml blood sample, the 
protamine was added and the syringe containing the protamine and blood mixture was 
inverted four times to ensure complete mixing. Immediately thereafter, the 10 ml blood 
specimen had 720 microlitres withdrawn for performance of the TEG’s® and 4.5ml 
thereof was added to a citrated tube for heparin activity (concentration) determination. 
The time frame cut-off for drawing of the blood, adding protamine, starting the TEG® 
and adding the sample to the citrated tube was limited to four minutes.   
Quality control was performed weekly with adequate acceptable reproducibility 
defined as being able to conduct three sets of TEGs with less than a 10% difference 
between parameters. The TEG® was stopped after the R-kaolin and R-heparinase 
times had been established. The difference in the R-kaolin and R-heparinase time 
denoted for this study as TEG® Delta-kh R-time was calculated and documented.  If 
r-times had not developed in the kaolin group before 60 minutes, the test was 
abandoned, but heparin activity was still determined.  
Determination of Heparin levels   
 
The citrated blood sample was placed on ice and dispatched to the NHLS within one 
hour of collection. The samples were centrifuged and the plasma stored at -80 degrees 
Celsius, at which temperature heparin is stable. Heparin assay was performed in 
batches using a modified anti-Xa chromogenic assay, the current gold standard 
method to measure heparin concentration.(9-11) A chromogenic assay, using a 
chromophore-linked substrate of factor-Xa cleaves the substrate by the active enzyme 
and subsequently releases a coloured compound. Prophylactic ranges for heparin are 
between 0.1 -0.4 IU/ml and therapeutic ranges are 0.3-0.7 IU/ml respectively.(10) The 
laboratory test incorporates known amounts of factor Xa and antithrombin III to the 
blood sample. The heparin forms an inhibitory complex with antithrombin III and 
inactivates factor Xa. The excess amount of factor Xa remaining in the sample is 
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inversely proportional to the original amount of heparin. The results are then compared 
to a standard curve and are provided in concentration of anti–factor Xa (units/mL).(10)  
 
Sample size estimation was performed using PASS software. We assumed a linear 
relationship between parameters, and that the regression equation would be a straight 
line, i.e. y = bx + c, where y is the dependent variable (heparin activity) and x is the 
independent variable (R time difference). Using the procedure for linear regression in 
the PASS software, we assumed the following: that standard deviation of the x values 
of 0, 0.5, 1.0, 1.5  was 0.56 (i.e. using fractional values rather than percentages), a 
power of 0.95 was required, a two sided alpha of 0.05, a slope of at least 0.5, and a 
Pearson’s product moment correlation coefficient (r) between x and y of at least 0.5.  
This revealed that a sample size of at least 42 samples would required to detect with 
95%  power the following relationship: A slope of 0.5 and a Pearson’s product moment 
correlation coefficient of 0.5 with a two sided alpha value of 0.05 assuming a standard 
deviation of the R time differences of 56%. As this was effectively a pilot study, we 
increased the sample size by approximately 50% to 60 samples to ensure that we do 
not incur a beta error should our sample size be estimations be somewhat incorrect.  
 
A purposely-designed form was used to collect the following clinical and laboratory 
data:  
1. Patient demographics; patient weight, length, gender, INR, PTT, platelet count, 
urea, creatinine, recent anticoagulants and surgical procedure/s performed.  
2. Haemoglobin concentration as measured by blood gas machine within the last 20 
minutes. 
3. TEG®R-kaolin (Rk) time and TEG® R-heparinase (Rh) time 
4. TEG® Delta-kh R-time (i.e the difference between kaolin and heparinise TEG) 
5. Heparin anti Xa assay (measured in IU/ml) 
The data was entered into a Microsoft Excel® spreadsheet for processing and 
thereafter, statistical analysis. 
 
  
Results 
Statistical analysis indicated that most data were normally distributed and had equal 
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variance but one-way, non-parametric analysis of variance (Kruskal-Wallace ANOVA) 
was required to analyse the difference between the protamine:heparin 0.25, 0.5, and 
0.75 mg/mg groups. This data is reported as medians (interquartile range (IQR)) with 
95% confidence intervals (95% CI). Differences between the R-kaolin and R-
heparinase times were analysed using a paired t-test. Pearson’s or Spearman’s 
correlation was used to determine whether relationships existed between parametric 
and non-parametric data respectively. Chi-squared test was used to detect differences 
in proportions. Logistic regression was used to identify which factor/s determined 
whether R-kaolin times were immeasurable and to derive a prediction probability 
equation. The results of the logistic regression interrogating the heparin concentration 
that predicted a measurable/immeasurable R-kaolin time, were subject to receiver 
operating curve (ROC) analysis.Twenty patients agreed to be enrolled. A total of 62 
blood samples (20 in group 0.25 mg/mg, 21 in group 0.5 mg/mg, and 21 in group 0.75 
mg/mg respectively) were taken. In three samples, technical errors precluded heparin 
concentration determination, this data being excluded from the analysis.  
 
R-kaolin time was longer than 90 minutes in 24 TEG® analyses, precluding R-kaolin 
time determination in these 24 cases.  
 
Surprisingly, Chi squared tests indicated the proportions of samples in which R-kaolin 
could not be determined did not differ between the Groups  (Table 1). Furthermore, 
Kruskal-Wallace one-way analysis of variance (ANOVA) revealed no between-group 
differences in any of the clotting parameters measured: in other words, there were no 
between group differences in ACT, R-kaolin times, R-heparinase times, or heparin 
concentrations (Table 2 ).  
 
No significant differences (p= 0.723) were identified between R-heparinase (10.4 (IQR 
8.8 to 12.8) minutes) and measurable R-Kaolin times (11.2 (IQR 9.7 to 13.3) minutes) 
(Figure 1). Furthermore, measurable R-kaolin and R-heparinase times were strongly 
correlated (r = 0.76, r2 = 0.57, p < 0.001) (Figure 2). Furthermore, in the 35 samples in 
which R-kaolin times were measurable, no relationships existed either between R-
kaolin times and heparin concentrations, p = 0.80 (Figure 3), or between TEG® Delta-
kh R- times and heparin concentrations (p = 0.42) (Figure 4).   
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Logistic regression was performed to determine whether an immeasurable R-kaolin 
time could be predicted. The dependent outcome (dichotomous variable) was a 
measurable or immeasurable R-kaolin time.  The independent variables investigated 
whether they could predict this outcome were protamine dose, heparin activity, R-
heparinase time, and ACT.  Heparin concentration was the only independent variable 
contained within the equation, the logistic regression equation being:  
 
 
Where P is the probability of the R-kaolin time being immeasurable, e is the base of 
the natural logarithm, and hep is heparin concentration. Heparin concentration could, 
in 86.6% and 50% of experiments, accurately predict that R-kaolin time would indeed 
be measurable and immeasurable respectively.  
 
ROC curve analysis of the logistic regression was performed, the classification 
variable being measurable versus immeasurable R-kaolin time.  This revealed an area 
under the curve (AUC) of 0.80 (95% CI 0.68 to 0.89), p < 0.0001, with optimum cut-off 
at heparin concentration greater than 1.24 IU/ml. At this value, sensitivity and 
specificity were 87.5% (95% CI 67.6% to 97.3%) and 71.1% (95% CI 54.1% to 84.6%), 
with positive and negative predictive values of 65.6% (95% CI 46.8% to 97.9%) and 
90.0% (95% CI 73.5% to 97.9%), respectively (Figure 5). 
 
 
Discussion 
We primarily investigated if TEG® point of care testing could accurately predict 
residual circulating heparin concentrations. We were unable to establish a relationship 
between heparin concentrations and TEG® Delta-kh R-time. It was therefore not 
possible to validate or refute our null hypothesis. However, ROC analysis of the data 
indicated that R-kaolin times will be measurable at heparin concentrations below 1.24 
IU/ml.  
  
It is critical to administer heparin before initiating cardiopulmonary bypass (CPB) and 
properly reverse its effect after CPB is terminated. Incomplete heparin reversal and 
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heparin rebound following CPB occurs in as many as 50% of patients(1) and may 
contribute to the high incidence (20%) of post- cardiopulmonary bypass bleeding.(1) 
Protamine reversal of heparin is traditionally guided by the use of timeous, point of 
care testing rather than remote, potentially delayed, laboratory testing.(3)  
 
ACT is a simple, convenient, widely accepted, point of care test used to indicate 
heparin activity. ACT is unable to measure actual heparin concentrations, but 
assesses the integrity of the intrinsic coagulation pathway processes. During 
cardiopulmonary bypass, it gauges the extent to which initial fibrin formation is affected 
by heparin. It is widely held that ACT increases linearly with increases in heparin 
concentration.(12, 13)  However, the relationship between ACT and heparin 
concentrations is distorted by hypothermia and haemodilution,(14), 
thromboctyopaenia, impaired platelet function, glycoprotein IIb/IIIa inhibitors,(4, 5) and 
aprotinin. The Hepcon® device is a haemostatic system measuring ACT and 
estimating whole blood heparin concentrations using automated protamine titration. 
Despotis et al. demonstrated anticoagulation management during cardiopulmonary 
bypass with the Hepcon® device to be more reliable than the standard ACT device.(4) 
 
Unfortunately, return of ACT to baseline is not an unqualified indicator of complete 
heparin reversal.(5) Indeed, research indicates that ACT is unreliable in predicting 
residual heparin. Galeone and colleagues described a poor relationship between 
plasma heparin concentrations and ACT. They concluded ACT is unable to detect 
residual heparin.(1) Guzetta et al investigated plasma heparin concentrations using 
three different ACT machines and found ACT to be an unreliable predictor of heparin 
concentration.(15) Effectively, ACT appears to be an insensitive point of care test to 
detect low residual levels of heparin, and the effects of heparin rebound. This was one 
of the rationales for this study.  
 
The thromboelastogram (TEG®) is a POC test measuring whole blood viscoelastic 
properties allowing for more dynamic information regarding the coagulation process. 
Information regarding initiation and formation of the clot, the strength thereof, 
coagulation factor interaction and their interaction with platelets, platelet function and 
fibrinolysis is obtained within a short period of time.  The R-time (reaction time) can be 
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available within 4-8 minutes and further information regarding clot kinetics within 10-
20 minutes (Figures 6 to 8). The rapid availability of such useful information is 
appealing during and after CPB. Laboratory tests (platelet count, prothrombin time, 
activated partial thromboplastin time and fibrinogen levels) are not only unable to 
provide information on clot kinetics, but also have a much greater delay between 
sampling and obtaining the results.(16) 
 
Heparin will affect the R-time alone, while other TEG® parameters are apparently 
unaffected by its presence.(1) An enzyme obtained from “flaviobacterium heparinum” 
called heparinase, may be added to the cuvette. Heparinase cleaves the 
polysaccharide portion of heparin, negating its effects and permitting the detection of 
non-heparin haemostatic problems.(1) If the R-kaolin time were prolonged, 
coagulation factor dysfunction would be a possibility. However, if R-kaolin time 
normalises after the addition of heparinase (R-heparinase time), the diagnosis of 
residual heparin can be made. Heparinase does not by itself affect TEG® 
variables.(17)  
 
Galeone and colleagues demonstrated that plasma heparin concentrations correlated 
well with TEG® R-times, but not ACT.(1). Indeed, TEG® may be more sensitive to 
(even low levels of) heparin activity than other point of care or laboratory (aPTT) 
tests.(1, 18) Levin and colleagues compared ACT and TEG® Delta-kh R-times as 
endpoints of protamine titration. However, neither test proved superior.(19) The lack 
of a difference in sensitivity between tests was possibly because kaolin-ACT and 
TEG® R-kaolin times measure similar things, and that TEG®  itself has a wide 
variability. 
 
Limitations of TEG® include its requirements to adhere to rigorous technical standards 
and quality controls, the need for trained personnel, and its wide, 20% variability. 
Native blood testing demonstrates less variability than citrated blood.(20) Citrated 
blood samples are affected by sample recalcification.(20) A criticism of TEG® is that 
it has never undergone the validation procedures mandatory for conventional 
haemostatic tests such as intra- and inter-observer variability, repeatability, 
calibration, and quality control.(21)  
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In our study, we attempted to determine the relationship between the TEG® Delta-kh 
R-time difference and heparin concentrations. The rationale was to assess post 
cardiopulmonary bypass residual heparin concentrations accurately using POC 
testing. R-kaolin and R-heparinase times did not differ and were highly correlated. 
There was no relationship between heparin Concentration (Activity) (IU/ml) and TEG® 
Delta kh R-time. TEG® Delta-kh R- time did not predict heparin concentrations.  
 
The question arises why a relationship between heparin concentrations and TEG® 
Delta-kh R-times could not be established? Baseline ACT, R-kaolin, and R-heparinase 
times were similar in all the groups suggesting that similar conditions existed in the 
groups when the blood was taken. Thus, this was not the problem. There was also no 
mistake in the measurement of the heparin concentrations, this being validated by the 
National Health Laboratory Service (NHLS) personnel. The most likely reasons lay in 
the complex calculations needed to calculate protamine titratation.   of based on. The 
assumptions we made with respect to calculation of blood volumes may not have been 
accurate. Furthermore, we titrated miniscule amounts of protamine (typically 0.02 to 
0.1 ml) using an insulin syringe, that could have introduced errors. These 
methodological issues will need to be overcome in similar future research. Future 
research would best circumvent this problem by sampling blood after incremental post 
cardiopulmonary bypass protamine administration. In retrospect, we originally 
deliberately avoided this study design as there were concerns that it would result in 
clumped data and prevent establishing the expected “linear” relationship. Alternatively, 
if the in vitro technique were reattempted, we would work at the higher concentrations 
of protamine and would need a larger sample size to establish a strong relationship.  
 
Our secondary outcome, determination of at what heparin concentrations R-kaolin 
times would become measurable, was successful. Logistic regression was able to 
predict the heparin concentrations at which R-time would and would not be 
measurable. ROC analysis revealed a high probability (negative predictive value 90% 
,95% CI 74% to 98%) of an immeasurable R-kaolin time when heparin concentrations 
exceeded 1.24 IU/ml. A measurable R-kaolin time was associated with a heparin 
concentration of less than 1.24 IU/ml, but with lesser certainty (65.6% (95% CI 46.8% 
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to 97.9%)). This observation can be utilised clinically. If R-kaolin time is measurable, 
the practitioner can deduce with reasonable certainty that that heparin concentrations 
are less than 1.24IU/ml.  
 
In conclusion, we wished to establish the relationship between the TEG® Delta-kh R-
time difference and heparin concentrations. Our results indicated a flawed study 
methodology that precluded identification of this relationship. We speculated as to the 
reasons for this result and suggest an alternative methodology in the future.  
 
However, the study did reveal useful information that has to our knowledge not yet 
been described. R-kaolin time will likely be measurable at heparin concentrations 
below 1.24 IU/ml, and not measurable at concentrations above that value. This is an 
observation that is immensely valuable for the clinician and also for the researcher.  
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